European Journal of Clinical and Experimental Medicine T.21, z. 4 (2023)

URI dla tej Kolekcjihttps://repozytorium.ur.edu.pl/handle/item/9493

Przeglądaj

Przeglądanie European Journal of Clinical and Experimental Medicine T.21, z. 4 (2023) według Autor "Bogucka, Julia"

Wpisz kilka pierwszych liter i kliknij przycisk Przeglądaj
Aktualnie wyświetlane 1 - 2 z 2
  • Obrazek miniatury
    Pozycja
    Hematopoietic stem cell transplantation in the treatment of HIV infection – comparison of “Berlin patient”, “London patient” and “Dusseldorf patient”
    (Publishing Office of the University of Rzeszow, 2023-12) Brzyska, Anna; Bogucka, Julia; Bojarska, Małgorzata Kinga; Domańska, Natalia Anna; Piecewicz-Szczęsna, Halina
    Introduction and aim. Human Immunodeficiency Virus-1 (HIV-1) remains one of the major issues in global public health. The standard therapy for HIV-1 positive patients includes using antiretroviral therapy (ART). These medications ensure suppression of viral replication but do not lead to a cure for the patient. The aim of this study was to present hematopoietic stem cell transplantation (HSCT) as a malignant treatment method which led to cure for three HIV-1 positive patients. Material and methods. Literature available in April 2023 was searched by using the PubMed and Google Scholar databases. Articles were selected using the following words: HIV, AIDS, HSCT therapy, ART therapy. Analysis of the literature. In each case of these described HSCT, the donor of hematopoietic stem cells had a homozygous mutation in the HIV co-receptor CCR5 (CCR5Δ32/Δ32). This mutation leads to a permanent lack of the protein and prevents penetration of virus by using this receptor. After transplantation, all of these 3 patients remained virus-free despite discontinuation of ART therapy. Conclusion. More research is needed to reduce the risk of using HSCT and perhaps in the future be able to use this therapy in all HIV-infected people.
  • Obrazek miniatury
    Pozycja
    The gut microbiota in development and treatment of depression
    (Publishing Office of the University of Rzeszow, 2023-12) Wilczek, Natalia; Bogucka, Julia; Brzyska, Anna; Sielwanowska, Wiktoria; Syzdoł, Bartłomiej; Piecewicz-Szczęsna, Halina
    Introduction and aim. Nowadays, almost 4% of people in the world suffer from depressive disorders, and the forecasts of further increase in incidence are alarming. The disease is debilitating and can lead to suicide, and available treatments are still imperfect. The aim of the study was to review the literature and present the potential role of the gut microbiota in the development of depression and to consider the use of prebiotics and probiotics as one of the therapeutic options in this disease. Material and methods. Review of articles published on PubMed since 2015. Analysis of the literature. The available reports point to a relationship between disturbances in the composition of the intestinal flora and the development of depressive disorders. In addition, more and more studies indicate the benefits of the influence on mood and clinical improvement, observed when using psychobiotics as an adjuvant treatment of depression, as well as monotherapy. Conclusion. Further research is needed in this area, especially in humans, to gain a deeper understanding of the role of the gut microbiota in depression and the promising use of psychobiotics for its treatment.